These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1219 related items for PubMed ID: 24144898

  • 21. 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
    Gagliardini R, Bandera A, Zaccarelli M, Sterrantino G, Latini A, D'Avino A, Lapadula G, Antinori A, Cauda R, De Luca A, Gori A, Di Giambenedetto S, Fabbiani M.
    Antivir Ther; 2018; 23(2):139-148. PubMed ID: 28799920
    [Abstract] [Full Text] [Related]

  • 22. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, Brinson C, Kulkarni R, Garner W, Ebrahimi R, Cao H, Cheng A, Szwarcberg J.
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [Abstract] [Full Text] [Related]

  • 23. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K, THRIVE study group.
    Lancet; 2011 Jul 16; 378(9787):229-37. PubMed ID: 21763935
    [Abstract] [Full Text] [Related]

  • 24. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
    Deeks ED.
    Drugs; 2014 Nov 16; 74(17):2079-95. PubMed ID: 25352394
    [Abstract] [Full Text] [Related]

  • 25. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
    Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E.
    HIV Clin Trials; 2013 Nov 16; 14(5):204-15. PubMed ID: 24144897
    [Abstract] [Full Text] [Related]

  • 26. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.
    J Acquir Immune Defic Syndr; 2014 Mar 01; 65(3):318-26. PubMed ID: 24525469
    [Abstract] [Full Text] [Related]

  • 27. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
    Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, Chen SS, McColl D, Holmes CB, Enejosa J, Toole JJ, Cheng AK.
    J Acquir Immune Defic Syndr; 2008 Jan 01; 47(1):74-8. PubMed ID: 17971715
    [Abstract] [Full Text] [Related]

  • 28. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
    DeJesus E, Ruane P, McDonald C, Garcia F, Sharma S, Corales R, Ravishankar J, Khanlou H, Shamblaw D, Ecker J, Ebrahimi R, Flaherty J, COMET Study Team.
    HIV Clin Trials; 2008 Jan 01; 9(2):103-14. PubMed ID: 18474495
    [Abstract] [Full Text] [Related]

  • 29. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P, Ribera E.
    Enferm Infecc Microbiol Clin; 2013 Jun 01; 31 Suppl 2():20-9. PubMed ID: 24252530
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S, Custodio JM, Wei X, Wang H, Fordyce M, Dave A, Ling KH, Szwarcberg J, Kearney BP.
    J Acquir Immune Defic Syndr; 2016 Jul 01; 72(3):281-8. PubMed ID: 26885802
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
    Huang WC, Huang CK, Huang SH, Lin SW, Ou ST, Chen YT, Chen YW, Chang SY, Liu WC, Sun HY, Hung CC.
    J Microbiol Immunol Infect; 2021 Oct 01; 54(5):944-951. PubMed ID: 32675042
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
    Sculier D, Gayet-Ageron A, Battegay M, Cavassini M, Fehr J, Hirzel C, Schmid P, Bernasconi E, Calmy A, Swiss HIV Cohort Study.
    BMC Infect Dis; 2017 Jul 06; 17(1):476. PubMed ID: 28683720
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 61.